Status:
RECRUITING
A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension
Lead Sponsor:
National Defense Medical Center, Taiwan
Conditions:
Artificial Intelligence (AI)
Artificial Intelligence (AI) in Diagnosis
Eligibility:
All Genders
50-85 years
Phase:
NA
Brief Summary
This study aims to validate the use of an artificial intelligence-enabled electrocardiogram (AI-ECG) to screen for elevated PAP. We hypothesize that the AI-ECG model can early identify patients with p...
Detailed Description
Pulmonary hypertension is often underdiagnosed due to extensive category of etiology. The diagnosis and treatment of pulmonary hypertension have changed dramatically through the re-defined diagnostic ...
Eligibility Criteria
Inclusion Criteria:
- Men or women, ≥ 50 to 85 years of age
- At least one 12-lead ECG within 3 months
Exclusion Criteria:
- A diagnosis of PH WHO Groups 1, 2, 3, 4, or 5
- A diagnosis of hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or infiltrative cardiomyopathy
- Prior heart, lung, or heart-lung transplants
- Any systolic pulmonary artery pressure >50 mmHg by echocardiography before
- Echocardiography in 3 months before index ECG
Key Trial Info
Start Date :
February 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 15 2026
Estimated Enrollment :
8666 Patients enrolled
Trial Details
Trial ID
NCT07079592
Start Date
February 1 2026
End Date
June 15 2026
Last Update
February 24 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Defense Medical Center
Taipei, Taiwan